14 hours Ago
PITTSBURGH , April 30, 2025 /PRNewswire/ -- Avista Therapeutics , a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced that the Company will present data highlighting the potential of its scAAVengr-HUnT platform to develop improved AAV capsids at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah taking place May 4-8, 2025 . Oral Presentation Details Title: Revolutionizing intravitreal gene therapy: Integrating machine learning-guided design of high-complexity AAV capsid libraries with the scAAVengr-HUnT platform Session Title: i3-guided gene therapy Date and Time: Wednesday, May 7 at 2:30-2:45 p.m.
MDT Presentation Number: 4651 Presenter: Laura Campello , Ph.D., Avista Therapeutics About Avista Therapeutics Avista Therapeutics' mission is to develop innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on patients' quality of life.
We leverage our computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors that target specific cell types using minimally invasive intravitreal delivery with reduced dosages. Our quantitative, in vivo-based approach and clinical ophthalmology expertise allow us to rapidly translate new gene therapies to the clinic. SOURCE Avista Therapeutics.
